Drug
Alks 8700
Alks 8700: highest development phase Phase 3, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALKS 8700 NCT03093324 | Phase 3 | Relapsing Remitting Multiple Sclerosis |
Latest
No recent events.
Follow Alks 8700 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.